Zacks Research Has Bullish Forecast for GSK FY2024 Earnings

GSK plc (NYSE:GSK) – Stock analysts at Zacks Research increased their FY2024 earnings per share (EPS) estimates for shares of GSK in a note issued to investors on Tuesday, November 19th. Zacks Research analyst E. Bagri now anticipates that the pharmaceutical company will post earnings of $4.12 per share for the year, up from their prior forecast of $4.11. The consensus estimate for GSK’s current full-year earnings is $4.03 per share. Zacks Research also issued estimates for GSK’s Q1 2026 earnings at $1.14 EPS and Q3 2026 earnings at $1.57 EPS.

GSK has been the topic of a number of other research reports. Argus raised GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Barclays raised GSK to a “hold” rating in a research report on Tuesday, August 27th. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and cut their target price for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Seven investment analysts have rated the stock with a hold rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Stock Up 0.8 %

NYSE GSK opened at $33.96 on Friday. The stock’s 50 day moving average is $38.09 and its 200 day moving average is $40.37. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. GSK has a 12 month low of $32.83 and a 12 month high of $45.92. The stock has a market cap of $70.37 billion, a PE ratio of 22.05, a P/E/G ratio of 1.29 and a beta of 0.66.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in GSK. FMR LLC increased its position in GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after buying an additional 2,224,345 shares in the last quarter. Primecap Management Co. CA increased its holdings in shares of GSK by 13.9% in the second quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company’s stock valued at $558,689,000 after purchasing an additional 1,773,020 shares during the period. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of GSK in the second quarter valued at about $52,487,000. Kahn Brothers Group Inc. acquired a new position in shares of GSK in the first quarter valued at about $53,743,000. Finally, Fisher Asset Management LLC increased its holdings in shares of GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after purchasing an additional 870,449 shares during the period. 15.74% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, major shareholder Plc Gsk acquired 2,791,930 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The stock was purchased at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the purchase, the insider now directly owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This trade represents a 19.97 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. 10.00% of the stock is currently owned by company insiders.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be paid a dividend of $0.3928 per share. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.63%. The ex-dividend date of this dividend is Friday, November 15th. GSK’s dividend payout ratio is 98.70%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.